4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights

28 Mar 2022 15:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Resignation of Professor David Schaffer, Ph.D. from the Company’s Board of Directors

22 Feb 2022 15:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

11 Feb 2022 15:03:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease at the 18th Annual WORLDSymposium

09 Feb 2022 07:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Present Updated Clinical Data with 4D-310 in Fabry Disease Patients in Platform Presentation at the 18th Annual WORLDSymposium

02 Feb 2022 15:01:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retinitis Pigmentosa

10 Jan 2022 07:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD

06 Jan 2022 15:03:04 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference

23 Nov 2021 15:05:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights

10 Nov 2021 15:01:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock

28 Oct 2021 20:06:48 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

26 Oct 2021 16:52:14 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia

25 Oct 2021 15:03:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting

10 Oct 2021 14:50:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD

06 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-710, an A101 Vector-based, Aerosol-delivered Gene Therapy for the Treatment of Cystic Fibrosis Lung Disease

06 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in Chardan’s 5th Annual Genetic Medicines Conference

29 Sep 2021 15:01:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting

24 Sep 2021 06:03:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights

12 Aug 2021 15:04:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License Agreement

24 Jun 2021 06:01:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Appoints Carolyne Zimmermann as Chief Business Officer

07 Jun 2021 06:00:00 By Nasdaq GlobeNewswire